Researchers Validate 14-Protein Blood Test Predicting Lung Cancer 5 Years Early
Updated
Updated · erictopol.substack.com · Jun 13
Researchers Validate 14-Protein Blood Test Predicting Lung Cancer 5 Years Early
3 articles · Updated · erictopol.substack.com · Jun 13
Summary
More than 80 researchers reported in Cell that a 14-protein blood signature predicted lung cancer an average 5.6 years before diagnosis and outperformed existing risk models based on demographics and smoking history.
Over 48,000 UK Biobank participants helped identify the marker from nearly 3,000 plasma proteins, and the signature was then validated across 8 additional cohorts, including a Taiwanese group in which 93% had never smoked.
Mechanistic work linked the proteins not to tumor cells but to stressed healthy bystander lung cells; particulate matter triggered macrophages to release interleukin-1β, amplifying the signal alongside cancer-driving mutations.
In a retrospective look at 2,325 CANTOS participants, people with the signature had more than double the lung-cancer risk, while canakinumab roughly halved that risk and cut the number needed to treat from 1,500 to 50 in the high-risk group.
The findings point toward a prevention strategy for lung cancer years before diagnosis, though researchers said a prospective clinical trial is still needed to prove the biomarker-guided approach works in practice.